NPT100-18A
NPT100-18A is an αSyn oligomerization inhibitor. NPT10018A rescues cleaved caspase-3 levels to control levels. NPT10018A attenuates mitochondrial oxidative stress probe levels in a compartment-specific manner and, at higher concentrations, increases ATP signals. NPT100-18A can be used for the study of Parkinson’s disease (PD).
For research use only. We do not sell to patients.
- Formula: C28H39N5O3
- Molecular Weight:493.64
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Caspase 3 |
NPT100-18A (10 nM) reduces the amount of Triton-X100 insoluble αSyn aggregated conformers in iPSC-derived mDANs[1].
NPT100-18A (10 nM) specifically reduces mitochondrial ROS in iPSC-derived mDANs without affecting total intracellular ROS[1].
NPT100-18A (1 µM) significantly increases ATP signaling in iPSC-derived mDANs[1].
NPT100-18A (10 nM, 21 days) significantly reduces the proportion of cCasp3⁺ neurons in iPSC-derived mDANs and inhibits the αSyn-related early neuronal apoptosis pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:mThy1-wt-α-syn transgenic mice[2].
-
Dosage:1 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg
-
Administration:I.p., once daily for 90 days
-
Result:10 and 20 mg/kg significantly reduced foot slips.
10 mg/kg significantly improved the error rate in the Challenger beam test.
Accumulation of α-synuclein in neurons and neurites was reduced.
SDS-resistant α-synuclein oligomers were reduced.
α-synuclein changed from a membrane component to a cytoplasmic component.
-
Animal Model:mThy1-E57K-α-syn transgenic mice[2].
-
Dosage:20 mg/kg
-
Administration:I.p., once daily for 90 days
-
Result:Significantly reduced α-syn dimer/trimer/polymers.
Oligomer accumulation decreased markedly.
Chemical Information
-
Molecular Weight 493.64
-
Formula C28H39N5O3
-
SMILES
O=C1N(CC2CCNCC2)CC(N(C(CCC3=CNC4=C3C=CC=C4)=O)CCC5=O)N5C1CCCC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Alecu JE, et al. NPT100-18A rescues mitochondrial oxidative stress and neuronal degeneration in human iPSC-based Parkinson's model. BMC Neurosci. 2025 Jan 28;26(1):8. [Content Brief]
[2]. Wrasidlo W, et al. A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease. Brain. 2016 Dec;139(Pt 12):3217-3236. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NPT100-18A Related Classifications
HY-156898 Related Classifications
Powered by Bioz